Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateConnectDistinguished InvestigatorsConferencesEducationRLT ComponentsSponsorsTrial Stats
First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma
Description:
The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in participants with metastatic uveal melanoma.
Sponsor:
Modulation Therapeutics, Inc.
Contacts:
Mark L McLaughlin, PhDmlm@modulationtherapeutics.com
813-784-0033
Karen E Hayes, PhDkarenh@modulationtherapeutics.com
304-906-7692
Government Study Link:
NCT05496686 - Click here to see study onClinicalTrials.gov
